Align Technology (ALGN) Receiving Somewhat Positive Press Coverage, Report Finds
Headlines about Align Technology (NASDAQ:ALGN) have trended somewhat positive on Saturday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Align Technology earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.6736537693089 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- NRG, Align Tech top year-end S&P 500; Frontier brings up the rear – Seeking Alpha (seekingalpha.com)
- Bay Area company is 2017’s top performer in S&P 500 – San Francisco Business Times (bizjournals.com)
- A Market Cynic’s Biotech Year In Review (finance.yahoo.com)
- Here’s What to Focus on – Align Technology, Inc. (NASDAQ: ALGN) – Alpha Beta Stock (alphabetastock.com)
A number of brokerages have recently issued reports on ALGN. Credit Suisse Group reiterated an “outperform” rating and set a $276.00 target price (up previously from $261.00) on shares of Align Technology in a research report on Tuesday, November 28th. Robert W. Baird reiterated a “buy” rating and set a $290.00 target price on shares of Align Technology in a research report on Wednesday, November 29th. Stifel Nicolaus increased their target price on Align Technology from $245.00 to $265.00 and gave the company a “buy” rating in a research report on Tuesday, November 21st. Morgan Stanley increased their target price on Align Technology from $257.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, November 27th. Finally, Deutsche Bank began coverage on Align Technology in a research report on Friday, December 8th. They set a “hold” rating and a $250.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $236.75.
Align Technology (ALGN) traded down $4.29 during midday trading on Friday, reaching $222.19. The company had a trading volume of 559,123 shares, compared to its average volume of 1,156,593. Align Technology has a 1 year low of $88.56 and a 1 year high of $266.41. The firm has a market cap of $18,158.64, a P/E ratio of 67.33, a P/E/G ratio of 2.15 and a beta of 1.43.
Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.19. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The firm had revenue of $385.30 million during the quarter, compared to the consensus estimate of $359.80 million. During the same period in the prior year, the company earned $0.63 EPS. The firm’s revenue was up 38.3% compared to the same quarter last year. equities analysts predict that Align Technology will post 3.65 EPS for the current fiscal year.
In other Align Technology news, Director Greg J. Santora sold 7,700 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $238.95, for a total value of $1,839,915.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Julie Tay sold 3,500 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $253.00, for a total value of $885,500.00. Following the completion of the sale, the vice president now directly owns 12,213 shares of the company’s stock, valued at $3,089,889. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,849 shares of company stock valued at $13,494,348. 1.60% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Align Technology (ALGN) Receiving Somewhat Positive Press Coverage, Report Finds” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/30/align-technology-algn-receiving-somewhat-positive-press-coverage-report-finds.html.
Align Technology Company Profile
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.